OVERVIEW
DOCUMENTS/REFERENCES
Biological Information
Background Information:
The binding of therapeutic compounds to plasma or serum proteins is a reversible, saturable process which can be an important factor in assessing the pharmacokinetic and pharmacodynamics profile of a drug. The extent of a drug’s binding to plasma and serum proteins is a determinant of drug distribution and elimination and is used as a factor in calculating in vivo hepatic clearance based on in vitro clearance The Eurofins assay uses equilibrium dialysis technique in a microplate format to determine the bound and unbound fraction and calculate the percentage of test compound binding to plasma proteins.
Organism:
Dog
Construct Details:
Endogenous
Tissue:
Plasma
Assay Information
Assay Type:
Physiochemical
Detection Method:
HPLC-MS/MS
Measured Response:
Peak Area Response
Testing Information
Test Concentration / Dose:
Assay is performed with a single concentration of 10 µM using 2 replicates
Test Sample Requirements:
Minimum for 1) Screen: 100 μl of 10 mM stock -OR- 1 to 2 mg (pre-weighed). 2) Dose Response: 250 μl of 10 mM stock -OR- 1.5 to 2 mg (pre-weighed).
Turnaround Time
Standard:
10 Business Days
Additional Information
Brand:
Cerep
Testing Location:
Spain - Murcia
RELATED SOLUTIONS
Protein binding (plasma, human) - ES
Item: 5224
Protein binding (plasma, mouse, CD-1) - ES
Item: 5225
Protein binding (plasma, rat, Sprague-Dawley) - ES
Item: 5226
Protein binding (plasma, monkey, Cynomolgus) - ES
Item: 5228
Questions? Contact Us
You can easily get in touch with a Eurofins Discovery Expert or get help from our Customer Service team. Reach out with questions, or to discuss your specific discovery challenges.
